To inform the resource allocation decision, we conducted this study to compare the cost-effectiveness of cemiplimab with pembrolizumab and atezolizumab as the first-line treatment for advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. This evidence concerns the gene CD274 and non-small cell lung carcinoma.